Weekly signal · GH · Healthcare

Guardant Health Inc (GH) posts another weekly gain within 54.5% 12-week run

The precision-oncology testing stock remains in an active weekly trend, though participation is not fully matching the price move.

Guardant Health Inc
Latest131.62 USD
1W move4.8%
Volume0.9x
TrendActive
Weekly chart context for Guardant Health shares alongside precision oncology diagnostics lab imagery.

Market update

What happened

Guardant Health Inc (GH) closed the latest week at 131.62 USD, up 4.8% on the weekly price path over 52 weeks.

Confirmation is visible in the 38.7% four-week return and positive Market Dynamics pressure at 1.11. The evidence is mixed, however, with 9.28 million shares traded versus a 13-week average of 10.55 million.

Continue your research

Explore GH across Sharemaestro

These links are shown because current Sharemaestro data is available for this company.

Interactive chartReview weekly price, Trend Line, Fair Value, volume and Relative Strength.Full weekly reportOpen the full company report, financial profile and peer comparison.Technical analysisExamine support, resistance, momentum and the current trend readings.Stage analysisSee whether the stock is basing, advancing, distributing or declining.Trend historyReview how long the current trend has persisted and where it has changed.Sector comparisonCompare sector returns, breadth, leaders and weaker areas.Industry comparisonSee how this company’s industry is performing across its members.Company factorsCompare value, quality, growth, momentum and financial strength.News sentimentSee the balance, quality and freshness of recent company coverage.Buying and selling pressureReview longer-term accumulation, distribution and reversal readings.EarningsReview report dates, estimates, past results and earnings surprises.Options activitySee options positioning, expected move and unusual trading activity.Short interestReview short positioning, crowding and possible squeeze risk.Insider transactionsSee reported purchases and sales by company directors and executives.

GH coverage

Evidence context